UniQure filed for accelerated FDA approval early this month. (uniQure) uniQure’s Huntington’s disease gene therapy has failed ...
Bitcoin’s reclaim of the $84,000 support zone now hinges on Treasury yields, fresh inflation data, and stronger ETF demand.
Qure (QURE) stock fell 48% after new Huntington's disease trial data missed the statistical bar in its AMT-130 gene therapy ...
A research team at the University of Vienna, led by pharmaceutical chemist Johannes Kirchmair, has developed a statistical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results